Katholisches Klinikum Koblenz Montabaur gGmbH — Clinical Trial Site

9 Registered trials

4 Currently recruiting

Organisation

Katholisches Klinikum Koblenz Montabaur gGmbH

Location

Koblenz, Germany

Identifier

ORG-100025979

Address

Rudolf-Virchow-Strasse 7, Rauental, 56073, Germany

Departments

Apotheke
Brustzentrum am Marienhof
Innere Medizin, Hämatologie und Onkologie Marienhof Koblenz
Kath. Klinikum Haus Marienhof Onkologische Tagesklinik
Katholisches Klinikum Koblenz Montabaur gGmbH
Klinik für Pneumologie, Onkologie und Beatmungsmedizin
Klinik für Pneumologie/ Onkologische Tagesklinik
N/A
Oncology

Clinical trials at this site (9)

Search interface

A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5 2026-06-12
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
A Study of Dato-DXd in Combination With Durvalumab and Carboplatin for First-line Treatment of Advanced NSCLC Without Actionable Genomic Alt… Ended

2023-505993-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2023-01-05
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun… Ended

2023-505981-26-00 Non−Small Cell Lung Cancer 5 2015-11-20